Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhakoss Spinal Implant May Be Safer Alternative To Allograft – Orthovita

This article was originally published in The Gray Sheet

Executive Summary

Orthovita is emphasizing its Rhakoss synthetic bone spinal implant as a potentially safer alternative to allograft for cervical spinal fusion surgery
Advertisement

Related Content

Orthovita Rhakoss
Orthovita Rhakoss
Orthovita Cortoss
Orthovita Cortoss
CDRH Examining CryoLife Heart Valve Risks Following Tissue Recall
CDRH Examining CryoLife Heart Valve Risks Following Tissue Recall
Kyphon Preparing IDE Submission For Spinal Bone Cement Filler, IPO
Sulzer Gearing Up To Ship BAK/C Cervical Fusion Cage In May
OrthoVita's Vitoss Gains 510(k) Clearance, Will List For $600-700
Tissue, Cell-Based Product Reg Needs Some Clarification - FDA Staffers
Advertisement
UsernamePublicRestriction

Register

MT017067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel